trending Market Intelligence /marketintelligence/en/news-insights/trending/_8kXsH-PJG4kTTAj3auBSQ2 content esgSubNav
In This List

Astellas' Suglat approved for type 1 diabetes mellitus in Japan

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Astellas' Suglat approved for type 1 diabetes mellitus in Japan

SNL Image

SNL Image

Astellas Pharma Inc. said its Suglat tablets have been approved in Japan for treating type 1 diabetes mellitus.

The drug was granted Japanese marketing approval for treating type 2 diabetes mellitus in January 2014.

People with diabetes have abnormally high blood sugar levels. In type 1 diabetes, the patient's body does not produce insulin — a hormone needed to keep blood sugar levels in check — while in type 2 diabetes, patients do not respond to insulin as well as they should.

Suglat was discovered through a collaboration between Tokyo's Astellas and Hanishina, Japan-based Kotobuki Pharmaceutical Co. Ltd.